Author/Creator: Buisseret, L. - British Library Electronic Legal Deposit Catalogue-Journal Issues and Articles Search Results

Author/Creator Buisseret, L.

1. 224P Immune characterization of de novo metastatic breast cancer. (December 2022)

Authors:: Yernaux, M.; Chretien, S.; Rothé, F.; Wang, X.; Rouas, G.; Boisson, A.; Kotecki, N.; Mailliez, A.; Larsimont, D.; Venet, D.; Sotiriou, C.; Buisseret, L.
Journal:: Immuno-oncology technology
Issue:: Volume 16(2022)Supplement 1
Page Start:
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

2. 50PLYMPHOCYTES INFILTRATING BREAST CANCER : DENSITY, COMPOSITION AND ORGANIZATION. (May 2014)

Authors:: Buisseret, L.; Garaud, S.; Duvillier, H.; Naveaux, C.; Duquenne, S.; de Wind, A.; Vakili, J.; Sotiriou, C.; Willard-Gallo, K.
Journal:: Annals of oncology
Issue:: Volume 25(2014)Supplement 1
Page Start:: i17
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

3. Immuno-oncology-101: overview of major concepts and translational perspectives. (October 2018)

Authors:: Allard, B.; Aspeslagh, S.; Garaud, S.; Dupont, F.A.; Solinas, C.; Kok, M.; Routy, B.; Sotiriou, C.; Stagg, J.; Buisseret, L.
Journal:: Seminars in cancer biology
Issue:: Volume 52(2018)Part 2
Page Start:: 1
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

4. Pembrolizumab for metastatic triple-negative breast cancer (mTNBC): long-lasting responses in the phase Ib KEYNOTE-012 study. (February 2017)

Authors:: Nanda, R.; Specht, J.; Dees, E.C.; Berger, R.; Gupta, S.; Geva, R.; Pusztai, L.; Pathiraja, K.; Ray, A.; Karantza, V.; Buisseret, L.
Journal:: European journal of cancer
Issue:: Volume 72(2017)Supplement 1
Page Start:: S38
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

5. PO-1185 Targeting therapy-resistant metastatic clones with SBRT in oligoprogressive breast cancer. (May 2022)

Authors:: Van den Begin, R.; Bellal, S.; De Caluwé, A.; Aftimos, P.; Paquier, Z.; Gebhart, G.; Buisseret, L.; Martinive, P.; Lefranc, F.; Van Gestel, D.
Journal:: Radiotherapy and oncology
Issue:: Volume 170(2022)Supplement 1
Page Start:: S1005
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

6. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials. (June 2017)

Authors:: Solinas, C.; Ceppi, M.; Lambertini, M.; Scartozzi, M.; Buisseret, L.; Garaud, S.; Fumagalli, D.; de Azambuja, E.; Salgado, R.; Sotiriou, C.; Willard-Gallo, K.; Ignatiadis, M.
Journal:: Cancer treatment reviews
Issue:: Volume 57(2017)
Page Start:: 8
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗